See more : The Aaron’s Company, Inc. (AAN) Income Statement Analysis – Financial Results
Complete financial analysis of GBS Inc. (GBS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GBS Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Korian (KORI.PA) Income Statement Analysis – Financial Results
- Loblaw Companies Limited (L-PB.TO) Income Statement Analysis – Financial Results
- Aryaman Capital Markets Limited (ARYACAPM.BO) Income Statement Analysis – Financial Results
- Group Psagot for Finance and Investments Ltd (GPST.TA) Income Statement Analysis – Financial Results
- Banco Bilbao Vizcaya Argentaria, S.A. (BBVXF) Income Statement Analysis – Financial Results
GBS Inc. (GBS)
About GBS Inc.
GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
---|---|---|---|---|---|---|
Revenue | 1.26M | 437.15K | 1.98M | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 930.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 326.67K | 437.15K | 1.98M | 0.00 | 0.00 | 0.00 |
Gross Profit Ratio | 25.99% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 0.00 | 3.85M | 3.84M | 588.21K | 3.18M | 2.53M |
General & Administrative | 0.00 | 4.92M | 3.72M | 2.43M | 3.55M | 2.08M |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 8.03M | 4.92M | 3.72M | 2.43M | 3.55M | 2.08M |
Other Expenses | 0.00 | -437.15K | -1.98M | 0.00 | 0.00 | 0.00 |
Operating Expenses | 8.03M | 8.34M | 5.57M | 3.02M | 6.73M | 4.60M |
Cost & Expenses | 8.96M | 8.34M | 5.57M | 2.83M | 6.73M | 4.60M |
Interest Income | 9.68K | 14.43K | 13.81K | 97.00 | 188.00 | 564.00 |
Interest Expense | -223.53K | 7.54K | 1.09M | 457.75K | 664.84K | 453.87K |
Depreciation & Amortization | -966.73K | 38.36K | -370.20K | 150.96K | 57.88K | 36.96K |
EBITDA | -13.56M | -8.30M | -5.94M | -2.68M | -6.67M | -4.57M |
EBITDA Ratio | -1,079.03% | -1,898.34% | -300.11% | 0.00% | 0.00% | 0.00% |
Operating Income | -12.60M | -8.34M | -5.57M | -2.83M | -6.73M | -4.60M |
Operating Income Ratio | -1,002.11% | -1,907.11% | -281.42% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | 1.96M | 2.90K | -1.49M | -335.96K | -664.65K | -453.31K |
Income Before Tax | -10.63M | -8.33M | -7.06M | -3.16M | -7.39M | -5.06M |
Income Before Tax Ratio | -845.89% | -1,906.45% | -356.49% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 0.00 | -38.36K | -22.92K | -29.17K | -57.69K | -36.39K |
Net Income | -10.63M | -8.30M | -7.04M | -3.13M | -7.34M | -5.02M |
Net Income Ratio | -845.89% | -1,897.68% | -355.33% | 0.00% | 0.00% | 0.00% |
EPS | -10.58 | -0.57 | -0.52 | -0.28 | -0.65 | -0.44 |
EPS Diluted | -10.58 | -0.57 | -0.52 | -0.28 | -0.65 | -0.44 |
Weighted Avg Shares Out | 1.00M | 14.67M | 13.58M | 11.29M | 11.29M | 11.29M |
Weighted Avg Shares Out (Dil) | 1.00M | 14.67M | 13.58M | 11.29M | 11.29M | 11.29M |
GBS, Inc. (GBS) Q4 2022 Earnings Call Transcript
GBS Inc. to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on August 31
GBS Inc. to Present at the H.C. Wainwright Global Investment Conference
GBS Inc.'s (GBS) CEO Dr. Steven Boyages on Q3 2022 Results - Earnings Call Transcript
GBS Inc. to Present Third Quarter 2022 Financial Results and Recent Corporate Update on May 10
4 Trending Penny Stocks to Add to Your Watchlist Right Now
GBS Inc. to Participate in the Upcoming March Investor Conferences
GBS Inc. (GBS) CEO Steven Boyages on Q2 2022 Results - Earnings Call Transcript
GBS Inc. to Present Second Quarter 2022 Financial Results and Recent Corporate Update on February 10
GBS Inc. to Participate in the Upcoming January Virtual Investor Conferences
Source: https://incomestatements.info
Category: Stock Reports